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ABCA7 frameshift deletion associated
with Alzheimer disease in African
Americans
ABSTRACT
Objective: To identify a causative variant(s) that may contribute to Alzheimer disease (AD) in
African Americans (AA) in the ATP-binding cassette, subfamily A (ABC1), member 7 (ABCA7)
gene, a known risk factor for late-onset AD.
Methods: Custom capture sequencing was performed on ;150 kb encompassing ABCA7 in 40
AA cases and 37 AA controls carrying the AA risk allele (rs115550680). Association testing was
performed for an ABCA7 deletion identified in large AA data sets (discovery n 5 1,068; replica-
tion n 5 1,749) and whole exome sequencing of Caribbean Hispanic (CH) AD families.
Results: A 44-base pair deletion (rs142076058) was identified in all 77 risk genotype carriers,
which shows that the deletion is in high linkage disequilibrium with the risk allele. The deletion
was assessed in a large data set (531 cases and 527 controls) and, after adjustments for age,
sex, and APOE status, was significantly associated with disease (p 5 0.0002, odds ratio
[OR] 5 2.13 [95% confidence interval (CI): 1.42–3.20]). An independent data set replicated
the association (447 cases and 880 controls, p 5 0.0117, OR 5 1.65 [95% CI: 1.12–2.44]),
and joint analysis increased the significance (p 5 1.414 3 1025, OR 5 1.81 [95% CI: 1.38–
2.37]). The deletion is common in AA cases (15.2%) and AA controls (9.74%), but in only 0.12%
of our non-Hispanic white cohort. Whole exome sequencing of multiplex, CH families identified the
deletion cosegregating with disease in a large sibship. The deleted allele produces a stable,
detectable RNA strand and is predicted to result in a frameshift mutation (p.Arg578Alafs) that
could interfere with protein function.
Conclusions: This common ABCA7 deletion could represent an ethnic-specific pathogenic alter-
ation in AD. Neurol Genet 2016;2:e79; doi: 10.1212/NXG.0000000000000079
GLOSSARY
AA5 African Americans; ABC 5 ATP-binding cassette; AD5 Alzheimer disease; CH5 Caribbean Hispanic; CI5 confidence
interval; GATK 5 Genome Analysis Toolkit; GWAS 5 genome-wide association study; OR 5 odds ratio; SNV 5 single-
nucleotide variant.
Alzheimer disease (AD) is the leading cause of dementia in the elderly. AD occurs at a higher
frequency in minority populations, with estimates of AD being twice as frequent in African
Americans (AA) compared with non-Hispanic white (NHW) populations.1,2 APOE was the
first gene associated with AD and the e4 allele confers an increased risk across populations.3,4
Although APOE e4 occurs more frequently in AA than NHW, paradoxically, it has a lower effect
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size in AA.5–7 Therefore, while differing
ethnicities share risk genes and alleles, the
consequences may be different in distinct
populations.
Recent studies have identified .20 addi-
tional loci associated with late-onset AD,
including ABCA7.8–10 Although ABCA7 was
first implicated in NHW, a genome-wide sig-
nificant signal was also detected in AA indi-
viduals at rs115550680, a position in linkage
disequilibrium with the NHW genome-wide
association study (GWAS) hits.8,9,11 The AA
allele confers a higher risk (p 5 2.21 3 1029,
odds ratio [OR] 5 1.79 [95% confidence
interval (CI): 1.47–2.12]) than the most sig-
nificantly associated alleles in NHW.7–9,11 The
effect size of the AA ABCA7 allele is compa-
rable to APOE e4 in AA (p 5 5.5 3 10247,
OR 5 2.31 [95% CI: 2.19–2.42]).7,11 To
date, there is no evidence of a functional con-
sequence of the AA ABCA7 risk allele.12–15
Therefore, targeted sequencing of ABCA7
was performed to identify potential causative
variants. A frameshift deletion was found asso-
ciated with AD in AA, but was virtually absent
in NHW. Thus, this deletion potentially rep-
resents a common, ethnic-specific, and likely
pathogenic alteration that confers risk to AD.
METHODS Standard protocol approvals, registrations,
and patient consents. All the individuals ascertained for this
study provided written informed consent prior to their inclusion.
If a study participant was not competent to provide consent, the
immediate next of kin or a legal representative provided written
consent on the behalf of the participant. All participants were as-
certained using a protocol that was approved by the appropriate
Institutional Review Board. Oversight of this study falls under
the University of Miami Institutional Review Board #20070307.
Sample collection. African Americans. Individuals were ascer-
tained for this study after they provided informed consent at the
John P. Hussman Institute for Human Genomics (HIHG) at the
University of Miami Miller School of Medicine (Miami, FL),
North Carolina A&T State University (Greensboro, NC), and
Case Western Reserve University (Cleveland, OH) for the HIHG
data set. Each of the participants was ascertained using the pro-
tocol approved by the proper institutional review boards (IRBs).
Patients were collected for this study over the course of 10 years,
with IRB protocols and amendments being approved at each
stage. For the HIHG cohort (discovery), 539 cases were ascer-
tained (415 women and 124 men, mean age at onset 74.0 years
[SD 8.5]) and 529 controls (403 women and 126 men, mean age
at examination 73.1 years [SD 5.4]). The complete HIHG case-
control AA cohort (n 5 1,068) included 47 relatives, giving
1,021 independent (unrelated) individuals available for analysis.
Samples from the Alzheimer’s Disease Genetics Consortium
(ADGC) were collected as described previously.11 For the ADGC
cohort (replication), 687 unrelated cases were ascertained (499
women and 188 men, mean age at onset 78.7 years [SD 8.5]) and
1,062 unrelated controls (774 women and 288 men, mean age at
examination 78.6 years [SD 6.7]). This subset of the ADGC
cohort was independent from the HIHG cohort.
For both HIHG and ADGC data sets, participants under-
went rigorous phenotyping and diagnostic criteria following those
of the National Institute of Neurological and Communicative
Disorders and Stroke—Alzheimer’s Disease and Related Disor-
ders Association, as described previously.11,15,16 Furthermore, the
cognitive status of controls was measured with either the Mini-
Mental State Examination (MMSE)17 or the Modified Mini-
Mental State (3 MS)18 and the Clinical Dementia Rating Scale,
which assesses functional decline.19 All the individuals in both
cohorts enrolled self-identified as African American. These data
were confirmed by analysis of existing GWAS data.11
Caribbean Hispanics. Nineteen multiplex Caribbean His-
panic (CH) families initially recruited as a part of the Genetic
Epidemiology of Alzheimer’s Disease In Hispanics family
study at Columbia University were included. A total of 49
cases and 8 unaffected relatives were involved in this study.
Information about patient recruitment, demographics, and
clinical phenotyping has been published previously.20 Each
family has at least one member with early-onset AD (age at
onset ,65 years old).
Custom capture and whole exome sequencing. Custom
sequence capture was performed on 77 HIHG samples of African
American ancestry (40 cases and 37 controls) all with the AA risk
allele. Probes were selected using the Agilent SureDesign program
across the region (chr19:983277-1133190, ;150 kb; Agilent
Technologies, Santa Clara, CA). Fourteen thousand six hundred
thirty-six probes were chosen at a 33 density with the moderately
stringent masking setting to cover 84.8% of the region. For whole
exome sequencing, samples from the 19 CH families were used
(46 cases and 6 unaffected relatives). Capture and sequence
library construction was performed on a Sciclone G3 NGS
Workstation (Caliper Life Sciences, PerkinElmer, Waltham,
MA) using the SureSelect Human All Exon 50 Mb Kit
(Agilent Technologies) and the Paired-End Multiplexed
Sequencing library kit (Illumina, San Diego, CA) for sequence
library preparation. All samples were run on the Illumina HiSeq
2000 and paired-end 2 3 100 sequencing was performed. The
sequencing data were processed using the Illumina Real-Time
Analysis base calling pipeline version 1.8. The Burrows-
Wheeler Aligner was used to map sequences to the hg19
human reference genome, and variant calling was performed
with the Genome Analysis Toolkit (GATK21,22). GATK
parameters included base quality score recalibration and
duplicate removal.23 The data were evaluated for deletions and
insertions by alignment with Bowtie2 and analysis using the
Pindel program.24,25
Sanger sequencing. Both the ABCA7 deletion (rs142076058)
and the AA ABCA7 risk allele (rs115550680) were sequenced
using traditional Sanger sequencing. Custom primers were de-
signed with the Primer3 v4.0 program (http://fokker.wi.mit.
edu/primer3/input.htm). For the deletion, primers were
selected to flank the 44-base pair (bp) deletion to perform
Sanger sequencing for validation (deletion-F: AAATCTTC
CCGCCTTGAGAT, deletion-R: GGAGCTTAGGGTGC
AGCTC). PCR experiments were set up with 1.5 mM
MgCl2, 1.6 M betaine, and touchdown PCR was performed.
PCR experiments resulted in amplicons of either 450 or 406
bp. Sequencing of the AA risk allele was performed with the
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following primers (rs115550680-F: GCCAATATGGCAAAA
CCATC, rs115550680-R: TCCAAAACCCTGTGATAGCC)
to generate a 245-bp amplicon. PCR reactions were set up with
2 mM MgCl2 and touchdown PCR was performed.
Sequencing reactions were performed using the Big Dye
Terminator v3.1 (Life Technologies, Carlsbad, CA),
reactions were run on a 3730xl DNA Analyzer (Life
Technologies), and results were evaluated using the
Sequencher v4.10.1 program (Gene Codes Corporation, Ann
Arbor, MI).
TaqMan SNP genotyping analysis. Both the ABCA7 dele-
tion (rs142076058) and the AA ABCA7 risk allele
(rs115550680) were evaluated using the TaqMan single-
nucleotide polymorphism (SNP) Genotyping Assays (Life
Technologies). The ABCA7 deletion was evaluated by
a custom-designed TaqMan SNP Genotyping Assays
designed to recognize the presence or absence of the
deletion. This assay had to be ordered as a “non-Human
Assay” (forward primer: GCCTGGATCTACTCCGTGAC,
reverse primer: GAGGCAGCTGAGGAACCA, FAM probe:
GAGACGCGGCTGG—identifies when the sequence is
deleted, VIC probe: CGCCATGGGGCT—wild-type allele).
Samples were amplified for 40 cycles and, when amplification
was low, an additional 20 cycles was added. The plates were
read on the 7900HT Fast Real-Time PCR machine (Applied
Biosystems, Foster City, CA), and data were analyzed with the
SDS v2.4 software.
RNA isolation and real-time PCR. RNA was isolated from
blood collected in PAXgene blood RNA tubes (PreAnalytiX,
Hombrechtikon, Switzerland) from 10 samples with and 10
samples without the ABCA7 deletion and extracted following
the manufacturer’s standard protocol. RNA was quantified on
the 2100 BioAnalyzer (Agilent Technologies) and was required
to have an RIN $6. Complementary DNA (cDNA) libraries
were generated using the iScript Reverse Transcriptase
Supermix for RT-qPCR kit (BIO-RAD). PCR primers were
designed to amplify the cDNA across the deletion (cDNA-F:
TGTTCCTGCGTGTGCTGA, cDNA-R: AGCAGGAAGC
TCTGGGTCAC) and the resulting PCR products resolved
on a 2% agarose gel. The wild-type allele results in an
amplicon of 316 bp, whereas the allele with the deletion
produces a 272-bp amplicon.
Statistical analysis. The GENMOD program, as part of the
SAS/STAT software, was used to perform the association tests
under a logistic regression model. Association tests were per-
formed with adjustments for age, sex, APOE status, and related-
ness between samples (SAS Institute, Cary, NC). Conditional
analysis was performed in PLINK.26 The Fisher exact test was
used to evaluate the differences in the alleles frequency of the
deletion between African and European populations reported in
the ExAC database.
RESULTS We selected 40 AA AD cases and 37 AA
controls (aged .65 years) carrying the AA risk allele,
rs115550680, to perform custom massively parallel
sequencing of a ;150-kb region that includes ABCA7
and 8 flanking genes and a small nuclear RNA. Samples
were sequenced to an average depth of over 1,0003 and
evaluated for single-nucleotide variants (SNVs) and
insertions and deletions. One thousand one hundred
twenty SNVs were detected by sequencing with 11
variants showing different frequencies in cases and
controls (p , 0.1, table e-1 at Neurology.org/ng). In
addition, a 44-base pair (bp) deletion (rs142076058,
p.Arg578Alafs) located ;3.5 kb upstream of the AA
risk allele was identified in all 77 individuals, which
suggests that it is in high linkage disequilibrium with
the risk allele (figure 1).
To further evaluate the rs142076058 deletion,
a custom TaqMan genotyping assay was designed to
evaluate the deletion in our larger AA cohort,
Figure 1 Location of the deletion in the ABCA7 gene and protein
(A) ABCA7 gene (chr19:1,040,103-1,065,571, hg38), 44-base pair deletion (blue), African American risk allele (blue and underlined11), and 3 non-Hispanic
white (NHW) risk alleles (rs3764650,8 rs3752246,9 and rs414792910). (B) Wild-type ABCA7 protein (2,146 amino acids) and the location of frameshift
deletion (blue) identified in this study. Below, the protein predicted to be generated from deletion would contain only 2 of the 11 transmembrane domains
(yellow) and neither of the 2 AAA domains (green), but incorporate 168 aberrant amino acids (black). The remaining frameshift, nonsense, and splicing
variants designated are rare alterations (,1%minor allele frequency) previously reported in NHW populations to be associated with Alzheimer disease.33–35
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designated as HIHG. After adjustments for age, sex,
and APOE status, the deletion was found to be sig-
nificantly associated with AD (p 5 0.0002, OR 5
2.13 [95% CI: 1.42–3.20], table 1) in 531 cases and
527 controls. The deletion occurred in 9.3% of con-
trol individuals but in 16.2% of AD cases. A subset of
8 individuals were pathologically confirmed cases of
AD; 2 were found to carry the deletion whereas the
remaining 6 did not. The AA risk allele was also
genotyped in this data set. The risk allele was signif-
icantly associated with AD (p 5 0.0005, OR 5 2.07
[95% CI: 1.38–3.13]) and in linkage disequilibrium
with the deletion (D9 5 1.000, r25 0.995, tables e-2
and e-3). The top SNPs in ABCA7 reported previ-
ously in NHW studies were also found to be in
linkage disequilibrium with the deletion (table
e-4).8,9,11 Genotyping was also performed on our
NHW AD samples (n 5 3,275), but only 4 individ-
uals were identified with the deletion (0.12%), all of
whom carried the AA risk allele, which indicates that
the genomic fragment carrying the deletion in these
individuals may be of African descent.
An independent AA data set from the Alz-
heimer’s Disease Genetics Consortium (ADGC)
was evaluated in the same manner, and the deletion
was again associated with AD (p 5 0.0117, OR 5
1.65 [95% CI: 1.12–2.44], table 1), occurring in
10.0% of control individuals and 14.9% of AD
cases. Joint analysis of the 2 cohorts increased
the strength of the association (p 5 1.414 3
1025, OR 5 1.81 [95% CI: 1.38–2.37], table 1).
Association testing was also performed for each data
set without APOE adjustment; more significant re-
sults were obtained with APOE adjustment, dem-
onstrating that APOE did not influence the
association (table e-5). Examination of the ages of
cases and controls with and without the deletion
did not find a significant difference between any of
these groups (table e-6).
To examine the association with AD in another
ethnic group with a high level of African ancestry
(;42%), we evaluated whole exome sequencing
data on 19 CH families from the Dominican
Republic with multiple affected AD participants.27
In addition to a relatively high level of African
ancestry, CHs are highly inbred and have a high
incidence of AD, and are thus enriched for AD
genetic risk factors.28 We independently identified
the same 44-bp deletion from whole exome
sequencing of 3 affected individuals from a large
CH family. Subsequent examination of the family
revealed that the deletion segregated in a large sib-
ship in the family (figure 2). Both the deletion and
AA risk allele were isolated in all 7 siblings who
clinically presented in a range from AD (individuals
5, 6, 8, 12, and 99) to milder stages of dementia
(individuals 7 and 11). Haplotype analysis around
the ABCA7 deletion using SNP data in the 1-Mb
flanking region on the family revealed that an
affected aunt who does not carry the deletion, indi-
vidual 3 (figure 2), has distinct ancestral haplotypes
from the family members in the large sibship with
the deletion (table e-7). This finding suggests that
individual 3’s AD phenotype can be attributed to
other genetic factors and that the ABCA7 deletion is
highly penetrant in the sibship. Because several
members of this CH family were known to have
early-onset AD (age at onset ,65 years), we exam-
ined the entire AA AD cohort (both HIHG and
ADGC) to determine whether there was an effect
of the deletion on age at onset in AD. We found no
Table 1 Association testing of the deletion in African American cohorts
Samples with deletion/
total samples (%) OR 95% CI Pr > jZj
HIHG
Cases 86/531 (16.2) 2.13 1.42–3.20 0.0002
Controls 49/527 (9.3)
ADGC
Cases 63/447 (14.9) 1.65 1.12–2.44 0.0117
Controls 88/880 (10.0)
Joint analysis
Cases 149/978 (15.2) 1.81 1.38–2.37 1.414 3 1025
Controls 137/1,407 (9.7)
Abbreviations: ADGC 5 Alzheimer’s Disease Genetics Consortium; CI5 confidence interval;
HIHG 5 John P. Hussman Institute for Human Genomics, University of Miami.
Figure 2 Pedigree of an AD family from the Dominican Republic with the ABCA7
deletion
Family 360 has 6 individuals diagnosed with Alzheimer disease (AD) and 2 individuals present-
ing with mild dementia. The numbers beneath each individual in the pedigree represent the in-
dividual’s sample number, the age at onset of AD (for AD cases) or the age at examination, and
the APOE genotype. All 7 siblings carry the ABCA7 deletion and the African Americans (AA)
risk allele, whereas individual 3 had neither the deletion nor the AA risk allele.
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difference in the age at onset in cases with the dele-
tion (75.6 years [SD 9.6]) compared with
cases absent for the deletion (76.8 years [SD 8.7],
p 5 0.09).
To determine whether the ABCA7 allele with the
deletion was being transcribed, RNA was isolated
from the blood of AA individuals both with and
without the ABCA7 deletion. Reverse transcription
PCR across the deletion region demonstrated that
the allele carrying the deletion is transcribed and pro-
duces a stable detectable RNA strand (figure 3).
This deletion was reported previously in the
Exome Aggregation Consortium (ExAC: http://
exac.broadinstitute.org) [June 2015], a repository
of 60,706 unrelated individuals from 6 distinct
ethnic groups. In the ExAC data set, the deletion
was found in 7.77% of individuals of African
ancestry and 0.95% of Latino individuals, but
was absent from individuals of European ancestry.
This difference in population frequencies between
the African and European populations was highly
significant (p , 1 3 10210).
DISCUSSION We identified a 44-bp deletion in
ABCA7 that is associated with AD in individuals of
African ancestry. Although the deletion did occur in
unaffected individuals, it was found at a higher
frequency in individuals with AD (15.2% of cases
vs 9.74% of controls), implicating it as a risk factor
for disease. This reaffirms that the deletion is likely to
be of African ancestry. Furthermore, the combined
cases from the HIHG and ADGC data sets had the
deletion at a frequency of 15.2%, approximately
twice as high as that identified with through ExAC
African populations (7.8%), lending additional
evidence of a relationship to disease. The deletion
was also independently identified in an AD family
from the Dominican Republic, a population that
has a relatively high level of African ancestry,
41.8%.27 Examination of the linkage disequilibrium
Figure 3 Deletion allele produces an RNA transcript
(A) Real-time PCR from cDNA of 3 samples without the ABCA7 deletion (1/1) and 3 samples heterozygous for the ABCA7
deletion (deletion/1). All samples produce an amplicon of 316 base pairs, but only the samples with deletion generate
a lower, 272-base pair amplicon (arrow). (B) Sanger sequencing from the 59 end of the deletion in an African American
control lacking the deletion and Alzheimer disease (AD)-specific line heterozygous for the deletion. The arrow denotes where
the deleted allele begins to be out of frame with the wild-type allele C. Sanger sequencing from the 39 end of the deletion
from the same control and AD individuals.
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of the deletion with the top 3 previously reported
SNPs found a high D9 across all locations, but only
a large r2 with the African-specific risk allele (table
e-4), further supporting that distinct alleles confer
AD risk in different ethnicities.8,9,11
The deletion is predicted to cause a frameshift at
amino acid 578, encoding for 168 incorrect amino
acids before stopping prematurely compared with
the largest isoform that generates a protein of
2,146 amino acids (figure 1B). Because we were
able to detect RNA from the allele with the dele-
tion, it is possible that this RNA generates an aber-
rant protein that interferes with the wild-type
2,146 amino acid protein. Within the first 578
amino acids, 2 transmembrane regions are con-
served and would be maintained by the mutated
protein (figure 1B). However, both AAA domains
and 9 additional transmembrane domains would be
predicted to be lost in this truncated protein, and
thereby interfere with the protein’s function of ex-
porting the lipid phosphatidylserine.29 Alterna-
tively, the shortened transcript may be subjected
to nonsense-mediated decay (NMD), as was seen
in the Glu709fs alteration identified in NHW.30
Although some loss-of-function variants in ABCA7
were identified in NHW populations that may con-
tribute to AD pathogenicity, these are rare variants
and may only partially contribute to the NHW
GWAS signal.30–32 A few previously reported loss-
of-function variants have demonstrated a functional
consequence including the Glu709fs variant under-
going NMD, and the c.557015G.C alteration
led to aberrant splicing30,31 (figure 1B). Therefore,
this study may be the first to connect a potentially
pathogenic and common alteration with a GWAS
signal in ABCA7.
ABCA7 is a member of the ATP-binding cassette
(ABC) transporter family, a large group of 49 genes
that encode for membrane proteins that facilitate the
movement of substrates across cell membranes.33,34
ABCA7 is expressed in the brain in neurons and mi-
croglia.35,36 There is evidence both in patients and
animal models demonstrating that inadequate levels
of ABCA7 may be directly correlated with Alzheimer
pathogenesis.37–39 The ABCA7 protein is involved in
the processing of amyloid precursor protein.40 In
addition, evidence has shown that ABCA7 acts in
the phagocytic pathway through extracellular signal-
regulated kinase signaling.e1,e2 ABCA7 is not the only
ABC transporter gene linked to AD; ABCA1,
ABCB1, ABCC1, ABCG1, ABCG2, and ABCG4 are
all implicated in Ab regulation.e3–e8 Furthermore,
a study identified rare loss-of-function alterations in
NHW patients diagnosed with Parkinson disease,
including specific variants previously reported in
AD individuals, which demonstrates that this gene
may contribute to the risk of multiple neurodegener-
ative disorders.e9
Therefore, the results of this study demonstrate
that there is a 44-bp deletion in ABCA7 that is asso-
ciated with AD and in linkage disequilibrium with
the previously identified AA risk allele. The deletion
was relatively frequent in our large AA AD cohorts,
independently identified in 1 of 19 CH AD families,
and virtually absent from our large NHWAD cohort.
Thus, the deletion could represent a common, ethnic-
specific alteration that confers risk of AD in popula-
tions with African ancestry.
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